Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 2/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310345 | 0.86 | CFTR (0.48) | SIRT2SIRT1SIRT3CFTRKDM4D | |
| SCHEMBL6302516 | 0.80 | POLB (0.52) | SIRT2SIRT1SIRT3CFTR | |
| SCHEMBL6305048 | 0.79 | SIRT3 (0.38) | SIRT2SIRT1SIRT3KDRMET | |
| SCHEMBL10224379 | 0.79 | MAPT (0.45) | SIRT2SIRT1SIRT3KDRMET | |
| SCHEMBL6302426 | 0.79 | KDR (0.39) | SIRT2SIRT1SIRT3KDRMET | |
| SCHEMBL5837898 | 0.78 | MAPT (0.39) | SIRT2SIRT1SIRT3KDRMET | |
| SCHEMBL5240306 | 0.78 | PDE4A (0.40) | SIRT2SIRT1SIRT3ADORA2AADORA2B | |
| SCHEMBL4709508 | 0.78 | MAPT (0.39) | SIRT2SIRT1SIRT3KDRMET | |
| SCHEMBL6302021 | 0.78 | MAPT (0.39) | SIRT2SIRT1SIRT3KDRMET | |
| SCHEMBL5837893 | 0.78 | MAPT (0.39) | SIRT2SIRT1SIRT3KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964961-B2 | Thiophene derivatives useful as anticancer agents | PFIZER INC (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1287001-B1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | TP53, RCC1, CCNA1 | SIRT2 1943/4885SIRT1 1929/4885SIRT3 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.